share_log

BMO Capital Maintains Outperform on Rigel Pharmaceuticals, Lowers Price Target to $3

Benzinga Real-time News ·  Nov 4, 2022 10:14

BMO Capital analyst Gary Nachman maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Outperform and lowers the price target from $4 to $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment